Iovance Biotherapeutics, Inc. (IOVA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol IOVA
- Company Iovance Biotherapeutics, Inc.
- Price $4
- Changes Percentage -5.44
- Change -0.23
- Day Low $3.98
- Day High $4.35
- Year High $5.63
- Year Low $1.66
- Market Cap $1,355,050,987
- Price Avg 50 EMA (D) $3.66
- Price Avg 200 EMA (D) $2.88
- Exchange NASDAQ
- Volume 9,228,455
- Average Volume 15,648,438
- Open $4.29
- Previous Close $4.23
- EPS -0.92
- PE -4.12
- Earnings Announcement 2026-08-06 12:30:00
- Shares Outstanding $357,533,242
Company brief: IOVANCE BIOTHERAPEUTICS, INC. (IOVA )
- Healthcare
- Biotechnology
- Dr. Frederick G. Vogt Esq., J.D., Ph.D.
- https://www.iovance.com
- US
- N/A
- 10-15-2010
- US4622601007
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.